Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Progress and Opportunities to Advance Clinical Cancer Therapeutics Using Tumor Dynamic Models
René Bruno, Dean Bottino, Dinesh P. de Alwis, et al.
Clinical Cancer Research (2019) Vol. 26, Iss. 8, pp. 1787-1795
Open Access | Times Cited: 72

Showing 1-25 of 72 citing articles:

Cell surface GRP78: An emerging imaging marker and therapeutic target for cancer
Masoud Farshbaf, Ahmad Yari Khosroushahi, Solmaz Mojarad-Jabali, et al.
Journal of Controlled Release (2020) Vol. 328, pp. 932-941
Open Access | Times Cited: 80
Treatment of evolving cancers will require dynamic decision support
Maximilian Strobl, Jill Gallaher, Mark Robertson‐Tessi, et al.
Annals of Oncology (2023) Vol. 34, Iss. 10, pp. 867-884
Open Access | Times Cited: 28
A comprehensive regulatory and industry review of modeling and simulation practices in oncology clinical drug development
Ana Ruíz‐García, Paul Baverel, Dean Bottino, et al.
Journal of Pharmacokinetics and Pharmacodynamics (2023) Vol. 50, Iss. 3, pp. 147-172
Open Access | Times Cited: 24
Applications of Artificial Intelligence in Drug Repurposing
Zhaoman Wan, Xinran Sun, Yi Li, et al.
Advanced Science (2025)
Open Access | Times Cited: 1
Artificial Intelligence and Mechanistic Modeling for Clinical Decision Making in Oncology
Sébastien Benzekry
Clinical Pharmacology & Therapeutics (2020) Vol. 108, Iss. 3, pp. 471-486
Open Access | Times Cited: 69
Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno‐Oncology and Beyond: Challenges, Perspectives, and Prospects
Haiqing Dai, Yulia Vugmeyster, Naveen Mangal
Clinical Pharmacology & Therapeutics (2020) Vol. 108, Iss. 6, pp. 1156-1170
Open Access | Times Cited: 63
AI-enhanced simultaneous multiparametric 18F-FDG PET/MRI for accurate breast cancer diagnosis
Valeria Romeo, Paola Clauser, Sazan Rasul, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2021) Vol. 49, Iss. 2, pp. 596-608
Open Access | Times Cited: 44
Realizing the promise of Project Optimus: Challenges and emerging opportunities for dose optimization in oncology drug development
Wei Gao, Jiang Liu, Blerta Shtylla, et al.
CPT Pharmacometrics & Systems Pharmacology (2023) Vol. 13, Iss. 5, pp. 691-709
Open Access | Times Cited: 23
Clinical Pharmacology Applications of Real‐World Data and Real‐World Evidence in Drug Development and Approval–An Industry Perspective
Rui Zhu, Bianca Vora, Sujatha Menon, et al.
Clinical Pharmacology & Therapeutics (2023) Vol. 114, Iss. 4, pp. 751-767
Open Access | Times Cited: 20
Predicting Radiotherapy Patient Outcomes with Real-Time Clinical Data Using Mathematical Modelling
Alexander P. Browning, Thomas D. Lewin, Ruth E. Baker, et al.
Bulletin of Mathematical Biology (2024) Vol. 86, Iss. 2
Open Access | Times Cited: 7
Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150
René Bruno, Mathilde Marchand, Kenta Yoshida, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 6, pp. 1047-1055
Open Access | Times Cited: 15
Support to early clinical decisions in drug development and personalised medicine with checkpoint inhibitors using dynamic biomarker-overall survival models
René Bruno, Pascal Chanu, Matts Kågedal, et al.
British Journal of Cancer (2023) Vol. 129, Iss. 9, pp. 1383-1388
Open Access | Times Cited: 14
Dose Optimization in Oncology Drug Development: An International Consortium for Innovation and Quality in Pharmaceutical Development White Paper
Divya Samineni, Karthik Venkatakrishnan, Ahmed A. Othman, et al.
Clinical Pharmacology & Therapeutics (2024) Vol. 116, Iss. 3, pp. 531-545
Open Access | Times Cited: 6
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
Sonoko Kawakatsu, René Bruno, Matts Kågedal, et al.
British Journal of Clinical Pharmacology (2020) Vol. 87, Iss. 6, pp. 2493-2501
Open Access | Times Cited: 33
Modelling glioma progression, mass effect and intracranial pressure in patient anatomy
Jana Lipková, Bjoern Menze, Benedikt Wiestler, et al.
Journal of The Royal Society Interface (2022) Vol. 19, Iss. 188
Open Access | Times Cited: 21
Explainable deep learning for tumor dynamic modeling and overall survival prediction using Neural-ODE
Mark Laurie, James Lu
npj Systems Biology and Applications (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 12
Prediction of overall survival in patients across solid tumors following atezolizumab treatments: A tumor growth inhibition–overall survival modeling framework
Phyllis Chan, Mathilde Marchand, Kenta Yoshida, et al.
CPT Pharmacometrics & Systems Pharmacology (2021) Vol. 10, Iss. 10, pp. 1171-1182
Open Access | Times Cited: 27
Computing the Hazard Ratios Associated With Explanatory Variables Using Machine Learning Models of Survival Data
Sameer Sundrani, James Lu
JCO Clinical Cancer Informatics (2021), Iss. 5, pp. 364-378
Open Access | Times Cited: 25
In Silico Investigations of Multi-Drug Adaptive Therapy Protocols
Daniel S. Thomas, Luis Cisneros, Alexander R.A. Anderson, et al.
Cancers (2022) Vol. 14, Iss. 11, pp. 2699-2699
Open Access | Times Cited: 19
Hypothetical generalized framework for a new imaging endpoint of therapeutic activity in early phase clinical trials in brain tumors
Benjamin M. Ellingson, Elizabeth R. Gerstner, Andrew B. Lassman, et al.
Neuro-Oncology (2022) Vol. 24, Iss. 8, pp. 1219-1229
Open Access | Times Cited: 17
Stronger together: a cross-SIG perspective on improving drug development
Luke Fostvedt, Jiawei Zhou, Anna Kondic, et al.
Journal of Pharmacokinetics and Pharmacodynamics (2025) Vol. 52, Iss. 1
Closed Access
Predicting tumor dynamics in treated patients from patient-derived-xenograft mouse models: a translational model-based approach
D. Ronchi, Elena M. Tosca, Paolo Magni
Journal of Pharmacokinetics and Pharmacodynamics (2025) Vol. 52, Iss. 3
Open Access
Enhanced Detection of Treatment Effects on Metastatic Colorectal Cancer with Volumetric CT Measurements for Tumor Burden Growth Rate Evaluation
Michael L. Maitland, Julia Wilkerson, Sanja Karovic, et al.
Clinical Cancer Research (2020) Vol. 26, Iss. 24, pp. 6464-6474
Open Access | Times Cited: 26
Early response dynamics predict treatment failure in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with cetuximab and nivolumab
Daniel J. Glazar, Matthew Johnson, Joaquim M. Farinhas, et al.
Oral Oncology (2022) Vol. 127, pp. 105787-105787
Closed Access | Times Cited: 16
Application of Machine Learning for Tumor Growth Inhibition – Overall Survival Modeling Platform
Phyllis Chan, Xiaofei Zhou, Na Wang, et al.
CPT Pharmacometrics & Systems Pharmacology (2020) Vol. 10, Iss. 1, pp. 59-66
Open Access | Times Cited: 23
Page 1 - Next Page

Scroll to top